Left ventricular hypertrophy and angiotensin II antagonists

Area of Science:

• Cardiology
• Hypertension Research
• Pharmacology

Background:

• Left ventricular hypertrophy (LVH) in hypertensive patients is a significant predictor of mortality and cardiovascular complications.
• The renin-angiotensin system (RAS) activation, specifically excessive angiotensin II production, is a key factor in LVH pathogenesis.
• Selective angiotensin II antagonists offer a potential therapeutic strategy for LVH regression.

Purpose of the Study:

• To evaluate the therapeutic efficacy of angiotensin II antagonists in reversing left ventricular hypertrophy (LVH) in hypertensive patients.
• To summarize the clinical evidence supporting the use of angiotensin II antagonists for LVH regression.
• To highlight the role of angiotensin II blockade in managing hypertensive heart disease.

Main Methods:

• Review of published clinical evidence, including open-label and randomized studies.
• Analysis of studies investigating the effects of specific angiotensin II antagonists (e.g., losartan, valsartan, irbesartan, candesartan) on LVH.
• Assessment of treatment outcomes related to the regression of left ventricular hypertrophy.

Main Results:

• Clinical studies demonstrate significant efficacy of angiotensin II antagonists in reversing left ventricular hypertrophy (LVH) in hypertensive individuals.
• Losartan has been extensively studied, showing positive results in LVH regression.
• Evidence for other agents like valsartan, irbesartan, and candesartan is emerging but less extensive.

Conclusions:

• Angiotensin II antagonists are effective antihypertensive agents that promote the regression of left ventricular hypertrophy (LVH).
• Blocking the renin-angiotensin system provides a valuable therapeutic approach to mitigate cardiovascular risks associated with LVH in hypertension.
• Further research on various angiotensin II antagonists can provide comprehensive data on LVH regression.